Overall, a clear progression was seen in the animal models across the NAFLD disease spectrum, with RC-fed Nrf2+/+ mice representing normality; RC-fed Nrf2−/− mice and HF-fed Nrf2+/+ mice developing steatosis, worse in the latter; and HF-fed Nrf2−/− mice developing the complete NASH phenotype with fibrosis. The gene discussed is NFE2L2; the disease is metabolic dysfunction-associated steatotic liver disease.